Drug
Tremelimumab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Checkpoint Inhibitors |
| Group | Anti-CTLA-4 mAb |
| Mechanism of Action | CTLA-4 inhibitor |
| Half-life | 16.9 d (single dose); 18.2 d (steady state) |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Immunologically synergistic via intratumoral Treg depletion and type-I IFN (Sharabi et al., Lancet Oncology, 2015; Formenti et al., Nature Medicine, 2018). The theoretical added risk is immune-mediated; loss of regulatory T-cell restraint provides a rationale for enhanced colitis/enterocolitis that could be additive with abdominopelvic RT-induced mucosal injury.
Data on this page refer exclusively to patients treated with
Tremelimumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Anti-CTLA-4 mAb group page.